Avalyn Pharma Inc. (AVLN) company profile
AVLNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026
$27.92−1.84 (-6.18%)
Close on Nov 17, 2026Market cap $1.24BP/E –Yield –
About Avalyn Pharma
Pharmaceutical Preparations, SIC 2834
Avalyn Pharma Inc. is listed on Nasdaq under the ticker AVLN, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Avalyn Pharma Inc.
- Headquarters
- Boston, MA
- Address
- 105 W First St. 02127
- Phone
- (206) 707-0340
- Website
- avalynpharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- AVLN
- Exchange
- Nasdaq
- IPO date
- Apr 30, 2026
- Shares outstanding
- 44M, Aug 31, 2026
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1540171
- CUSIP
- 05348Y105
- ISIN
- US05348Y1055
- FIGI
- BBG003M9S3Z4
- Share class FIGI
- BBG003M9S400
- EIN
- 45-2463191
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Lyn Baranowski | Chief Executive Officer, Director | – |
| Adam H. Golden | General Counsel | – |
| Melissa Rhodes | Chief Operating Officer | – |
| Douglas R. Carlson | Chief Financial Officer | – |
| Howard Lazarus | Chief Medical Officer | – |
| Robert J. Meyer | Director | – |
| Heather D. Turner | Director | – |
| Jon Congleton | Director | – |
| Kate Haviland | Director | – |
| Erin Lavelle | Director | – |
| Jill Carroll | Director | 1,419,298 |
| David Matthew Friedman | Director | – |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Apr 30, 2026
- Offer price
- $18.00
- Securities offered
- 16,666,667
- Gross proceeds
- $300.00M
- Exchange
- Nasdaq
- Lock-up ends (est.)
- Oct 27, 2026
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Apr 30, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Apr 27, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
| May 24, 2017 | Name change | Name changed from Genoa Pharmaceuticals, Inc. to Avalyn Pharma Inc. |
See a number that looks wrong?